. Adoption Value of serum Hematological Inflammatory Markers in Early Diagnosis of Necrotizing Enterocolitis
Inflammatory Markers in NEC Diagnosis
Abstract
Introduction: early diagnosis and intervention of neonatal necrotizing enterocolitis (NEC) are crucial for improving prognosis. It was to assess the diagnostic and staging value of high-sensitivity C-reactive protein (hs-CRP), white blood cell count (WBC), and interleukin (IL)-6 levels in NEC, and to explore their correlation with disease severity. Materials and Methods: this retrospective study analyzed clinical data from 43 NEC patients in the neonatology department of Northwest Women and Children’s Hospital, designated as the experimental group (EG), and concurrently selected 38 healthy newborns as the control group (CG). Serum hs-CRP, WBC, and IL-6 were measured in both groups. Statistical analyses were performed using SPSS 27.0. Results: hs-CRP, WBC, and IL-6 in NEC patients greatly surpassed those in healthy newborns, and these markers were notably positively correlated with NEC staging (r=0.756, 0.234, 0.901, P<0.05). Combined detection of hs-CRP, WBC, and IL-6 in early NEC diagnosis yielded an AUC of 0.988, with a sensitivity of 93.02% and specificity of 97.37%, all superior to individual detections (P<0.05). Conclusion: hs-CRP, WBC, and IL-6 have important value in diagnosis and assessment of NEC, particularly the combined detection which greatly improves early diagnostic accuracy. Future research should further investigate additional inflammatory markers to optimize diagnostic methods, providing a more comprehensive scientific basis for early clinical intervention and treatment.
References
Calvert, W., Sampat, K., Jones, M., Baillie, C., Lamont, G. and Losty, P.D., 2021. Necrotising enterocolitis-A 15-year outcome report from a UK specialist centre. Acta Paediatr., 110(2): 495-502. https://doi.org/10.1111/apa.15510
Chan, B., Gordon, S., Yang, M., Weekes, J. and Dance, L., 2021. Abdominal ultrasound assists the diagnosis and management of necrotizing enterocolitis. Adv. Neonatal. Care., 21(5): 365-370. https://doi.org/10.1097/ANC.0000000000000919
Chen, J., Yan, Z., Lin, Z., Fan, Y., Bao, X., Chen, X. and Zheng, A., 2024. I-FABP protein/mRNA and IL-6 as biomarkers of intestinal barrier dysfunction in neonates with necrotizing enterocolitis and SPF BALB/c mouse models. J. Int. Med. Res., 52(6): 3000605241254788. https://doi.org/10.1177/03000605241254788
Elfarargy, M.S., El Farargy, M.S., Atef, M.M., El-Deeb, O.S., Elsharaby, R.M. and Elhady, H.A.E., 2019. Early biomarkers in neonatal necrotizing enterocolitis: a pilot study. J. Popul. Ther. Clin. Pharmacol., 26(3): e1-e8. https://doi.org/10.15586/jptcp.v26i3.602
Gephart, S.M., Fleiner, M., Msowoya, A. and Rothers, J., 2023. Prediction of gutcheck NEC and its relation to severity of illness and measures of deterioration in necrotizing enterocolitis. Adv. Neonatal. Care., 23(4): 377-386. https://doi.org/10.1097/ANC.0000000000001080
Hansen, M.L., Jensen, I.V., Gregersen, R., Juhl, S.M. and Greisen, G., 2019. Gastrointestinal sequelae and growth impairment at school age following necrotising enterocolitis in the newborn period. Acta Paediatr., 108(10): 1911-1917. https://doi.org/10.1111/apa.14789
Huo, R., Liu, H., Chen, J., Sheng, H. and Miao, L., 2021. Serum HMGB1 level is correlated with serum I-FABP level in neonatal patients with necrotizing enterocolitis. BMC Pediatr., 21(1): 355. https://doi.org/10.1186/s12887-021-02818-6
Korkut, S., Özdemir, A., Yay, A.H., Yalçın, B., Ceylan, M., Korkmaz, L., Yazıcı, C., Güntürk, İ. and Kurtoğlu, S., 2019. Obestatin reduces intestinal damage in experimental necrotizing enterocolitis in newborn rats. Am. J. Perinatol., 36(11): 1179-1187. https://doi.org/10.1055/s-0038-1676491
Lamireau, N., Greiner, E. and Hascoët, J.M., 2023. Risk factors associated with necrotizing enterocolitis in preterm infants: a case-control study. Arch. Pediatr., 30(7): 477-482. https://doi.org/10.1016/j.arcped.2023.07.003
Lueschow, S.R., Boly, T.J., Jasper, E., Patel, R.M. and McElroy, S.J., 2022. A critical evaluation of current definitions of necrotizing enterocolitis. Pediatr. Res., 91(3): 590-597. https://doi.org/10.1038/s41390-021-01570-y
Ongun, H. and Demir, M., 2020. Mortality caused by late-onset sepsis in very low birth weight infants: risk analysis and the performance of diagnostic tools. J. Coll. Physicians Surg. Pak., 30(6): 611-616. https://doi.org/10.29271/jcpsp.2020.06.611
Ou, L., Liu, H.R., Shi, X.Y., Peng, C., Zou, Y.J., Jia, J.W., Li, H., Zhu, Z.X., Wang, Y.H., Su, B.M., Lai, Y.Q., Chen, M.Y., Zhu, W.X., Feng, Z., Zhang, G.M. and Yao, M.C., 2024. Terminalia chebula Retz. aqueous extract inhibits the Helicobacter pylori-induced inflammatory response by regulating the inflammasome signaling and ER-stress pathway. J. Ethnopharmacol., 320: 117428. https://doi.org/10.1016/j.jep.2023.117428
Pantalone, J.M., Liu, S., Olaloye, O.O., Prochaska, E.C., Yanowitz, T., Riley, M.M., Buland, J.R., Brozanski, B.S., Good, M. and Konnikova, L., 2021. Gestational age-specific complete blood count signatures in necrotizing enterocolitis. Front. Pediatr., 9: 604899. https://doi.org/10.3389/fped.2021.604899
Probert, C., Greenwood, R., Mayor, A., Hughes, D., Aggio, R., Jackson, R.E., Simcox, L., Barrow, H., García-Finana, M. and Ewer, A.K., 2020. Faecal volatile organic compounds in preterm babies at risk of necrotising enterocolitis: the DOVE study. Arch. Dis. Child. Fetal. Neonatal. Ed., 105(5): 474-479. https://doi.org/10.1136/archdischild-2019-318221
Qi, Y., Liu, C., Zhong, X., Ma, X., Zhou, J., Shi, Y., Yin, Y., Zhang, X., He, Y., Xu, W., 2021. IL-27 as a potential biomarker for distinguishing between necrotising enterocolitis and highly suspected early-onset food protein-induced enterocolitis syndrome with abdominal gas signs. EbioMedicine, 72: 103607. https://doi.org/10.1016/j.ebiom.2021.103607
Raba, A.A., O’Sullivan, A. and Miletin, J., 2021. Pathogenesis of necrotising enterocolitis: The impact of the altered gut microbiota and antibiotic exposure in preterm infants. Acta Paediatr., 110(2): 433-440. https://doi.org/10.1111/apa.15559
Schoenaker, M.H.D., Zuiderwijk, M.O., Bekker, V., Bredius, R.G.M., Werner, J., Schulze, J.J., van der Burg, M. and Blom, M., 2023. Epigenetic immune cell counting to analyze potential biomarkers in preterm infants: a proof of principle in necrotizing enterocolitis. Int. J. Mol.Sci., 24(3): 2372. https://doi.org/10.3390/ijms24032372
Su, W., Li, Y., Wang, Y., Li, L. and Yan, J., 2021. Correlation between 1-FABP, blood routine and grading of necrotising enterocolitis. J. Coll. Physicians Surg. Pak., 31(2): 238-239. https://doi.org/10.29271/jcpsp.2021.02.238
Yarci, E., Tayman, C., Ozturk Yarci, D., Cakir, U., Gonel, A. and Taskin Turkmenoglu, T., 2021. Inhibition of Interleukin-6 signaling: a novel therapeutic approach to necrotizing enterocolitis. Int. Immunopharmacol., 101(Pt B): 108358. https://doi.org/10.1016/j.intimp.2021.108358
Zheng, C.M., Piao, X.M., Byun, Y.J., Song, S.J., Kim, S.K., Moon, S.K., Choi, Y.H., Kang, H.W., Kim, W.T., Kim, Y.J., Lee, S.C., Kim, W.J. and Yun, S.J., 2022. Study on the use of Nanostring nCounter to analyze RNA extracted from formalin-fixed-paraffin-embedded and fresh frozen bladder cancer tissues. Cancer Genet., 268-269: 137-143. https://doi.org/10.1016/j.cancergen.2022.10.143
Zong, Z., Xin, L., Tang, X. and Guo, H., 2021. The clinical characteristics and prognostic value of IGFBP6 in glioma. Neurol. Res., 44(2): 113-120. https://doi.org/10.1080/01616412.2021.1963620
Zou, D., Hu, F., Zhou, Q. and Xu, X., 2023. miRNA-301 as a molecule promoting necrotizing enterocolitis by inducing inflammation. Acta Biochim. Pol., 70(4): 905-910. https://doi.org/10.18388/abp.2020_6806
Zvizdic, Z., Milisic, E., Jonuzi, A., Terzic, S., Zvizdic, D. and Vranic, S., 2021. The effects of ranitidine treatment on the risk of necrotizing enterocolitis in preterm infants: a case-control study. Acta Medica (Hradec Kralove), 64(1): 8-14. https://doi.org/10.14712/18059694.2021.2
Copyright (c) 2024 Pengfei Zhang
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.